Pretransplant Soluble CD30 Is a Better Predictor of Posttransplant Development of Donor-Specific Antibodies and Acute Vascular Rejection than Panel Reactive Antibodies

Abstract

These data support our hypothesis that patients positive for sCD30 contents are at high risk the development of DSA and AVR posttransplant regardless of their pretransplant PRA.